Psoralen plus ultraviolet A does not increase the risk of cataracts: a 25-year prospective study
- PMID: 17532094
- DOI: 10.1016/j.jaad.2007.04.027
Psoralen plus ultraviolet A does not increase the risk of cataracts: a 25-year prospective study
Abstract
Background: In some animal species, exposure of the unprotected eye to psoralen plus ultraviolet A (PUVA) therapy induces lens opacities. The relevance of these animal findings to human beings is not established. However, some case reports suggest that PUVA in human beings may increase the risk of lens abnormalities.
Objective: Our aim was to evaluate any possible associations between exposure to PUVA and increased risk of ocular lens abnormalities.
Methods: Since 1977 the PUVA follow-up study has periodically monitored the ocular status of 1237 cohort members with psoriasis using structured eye examinations. In our previous report we presented data results of the first 10 years of prospective study. This report includes data from two additional cycles of eye examinations that span an additional 14 years of follow-up.
Results: Based on our data from the last pre-1993 to final eye examination (2004), compared with that observed for the earlier period (first ever to last pre-1993 eye examination), the age-adjusted incidence of cataract did not increase significantly (incidence rate ratio = 1.04, 95% confidence interval = 0.82-1.31). In both the univariate and multivariate analyses increasing exposure to PUVA was not associated with a higher risk of cataract.
Limitations: Our cohort principally enrolled middle-aged or older patients so our data do not permit us to assess the effects of PUVA on the eyes of younger persons.
Conclusions: Increasing exposure to PUVA does not increase cataract risk among persons using eye protection at the rates used in our cohort.
Similar articles
-
The risk of melanoma in association with long-term exposure to PUVA.J Am Acad Dermatol. 2001 May;44(5):755-61. doi: 10.1067/mjd.2001.114576. J Am Acad Dermatol. 2001. PMID: 11312420
-
Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study.N Engl J Med. 1997 Apr 10;336(15):1041-5. doi: 10.1056/NEJM199704103361501. N Engl J Med. 1997. PMID: 9091799
-
The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective study.J Am Acad Dermatol. 2012 Apr;66(4):553-62. doi: 10.1016/j.jaad.2011.04.004. Epub 2012 Jan 20. J Am Acad Dermatol. 2012. PMID: 22264671
-
Ocular complications of PUVA therapy.Australas J Dermatol. 1993;34(1):1-4. doi: 10.1111/j.1440-0960.1993.tb00834.x. Australas J Dermatol. 1993. PMID: 8240180 Review.
-
Side-effects of psoralen photochemotherapy (PUVA).Br J Dermatol. 1990 Jun;122 Suppl 36:117-25. doi: 10.1111/j.1365-2133.1990.tb02889.x. Br J Dermatol. 1990. PMID: 2196078 Review.
Cited by
-
Skin Directed Therapy in Cutaneous T-Cell Lymphoma.Front Oncol. 2019 Apr 11;9:260. doi: 10.3389/fonc.2019.00260. eCollection 2019. Front Oncol. 2019. PMID: 31032224 Free PMC article. Review.
-
[Skin and eyes].Hautarzt. 2009 Jan;60(1):63-74; quiz 75. doi: 10.1007/s00105-008-1685-x. Hautarzt. 2009. PMID: 19130027 Review. German.
-
Ocular complications in adults with psoriasis: a cross-sectional study in a referral center in Brazil.Int Ophthalmol. 2024 May 5;44(1):215. doi: 10.1007/s10792-024-03147-0. Int Ophthalmol. 2024. PMID: 38705919 Free PMC article.
-
The Patient's Guide to Psoriasis Treatment. Part 2: PUVA Phototherapy.Dermatol Ther (Heidelb). 2016 Sep;6(3):315-24. doi: 10.1007/s13555-016-0130-9. Epub 2016 Jul 29. Dermatol Ther (Heidelb). 2016. PMID: 27474030 Free PMC article. Review.
-
Identifying and Treating Ocular Manifestations in Psoriasis.Am J Clin Dermatol. 2022 Jan;23(1):51-60. doi: 10.1007/s40257-021-00648-x. Epub 2021 Nov 3. Am J Clin Dermatol. 2022. PMID: 34731450 Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical